Jeff jonas sage

Author: swwl

August undefined, 2024

Web6 dic 2024 · Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’ In an interview with BioPharma Dive, the longtime industry executive discussed becoming a biotech investor and his plans for Abio-X, a new incubator with $150 million to spend on startups. Web10 nov 2024 · Sage announced this week that Jonas would leave the company to join a private equity firm. He has been part of the C-suite at Sage Therapeutics since 2013. He …

Sage names former Alnylam exec Barry Greene as …

WebScopri foto stock e immagini editoriali di attualità di Sage Therapeutics su Getty Images. Scegli tra immagini premium su Sage Therapeutics della migliore qualità. Web16 dic 2024 · Jeff Jonas, Sage’s CEO since 2013, will remain with the company as chief innovation officer. The official CEO handoff took place on Tuesday and was made public on Wednesday morning. fqhcs nyc

Sage-Biogen drug improves symptoms in postpartum depression …

Web19 mar 2024 · Sage Therapeutics (NASDAQ: ... change in the way postpartum depression is thought about and treated moving forward,” said Jeff Jonas, M.D., chief executive officer of Sage. “We are ... Web22 mar 2024 · To be marketed as Zulresso, it’s the first drug developed by and approved from Sage Therapeutics of Cambridge, Mass. Jeff Jonas, Sage’s CEO, recently chatted with STAT about the drug, its... Web6 dic 2024 · Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’. In an interview with BioPharma Dive, the longtime industry executive … fqkzcb

Sage Therapeutics Announces FDA Approval of ZULRESSO

Jeff jonas sage

Karuna Appoints Jeff Jonas, M.D., to Board of Directors

Web16 dic 2024 · Jeff Jonas, Sage’s CEO since 2013, will remain with the company as chief innovation officer. The official CEO handoff took place on Tuesday and was made public … WebDr. Jeff Jonas applies his 25+ years of well-recognized expertise in neuroscience, drug development, and pipeline expansion to his role as Chief Executive Officer at ABio-X. He …

Did you know?

WebOn this week’s Tech Nation, it’s about developing medicines which enable the body to heal itself. First up, treating depression in a whole new way … and rapidly. Dr. Jeff Jonas, the Chief Innovation Officer and Director of Sage Therapeutics, talks about their drug Zuranolone, nearing the end of its drug approval journey. Web31 mar 2024 · I’m proud of the way our employees, partners, and the community have responded in this unprecedented time,” said Jeff Jonas, M.D., chief executive officer at Sage Therapeutics. “The teams at Sage are handling virtual work well, and progress across our pipeline remains strong.

Web14 ago 2013 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system … Web10 nov 2024 · L ongtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech incubator with global investment giant CBC Group. Sage announced this week that Jonas...

Web12 giu 2015 · Jonas, 62, was then president of regenerative medicine at Shire Pharmaceuticals (Nasdaq: SHPG), but he said he turned down the offer at the time. … Web16 dic 2024 · Having Barry as CEO and Jeff as CInO strengthens Sage for its next evolution.”. Barry E. Greene joined the Sage Board of Directors in October 2024 bringing more than 30 years of experience to ...

Web22 ott 2024 · Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with …

Web17 feb 2024 · February 16, 2024 07:45 PM Eastern Standard Time CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Sage Therapeutics (NASDAQ: SAGE) - On February 16, 2024, Chief Executive Officer Jeff Jonas conducted... fqm vagasWeb4 ott 2024 · Jeffrey Jonas served as Chief Executive Officer of Sage Therapeutics from 2013 to 2024, where he engineered one of the industry's leading product pipelines in … fqnyWeb23 apr 2024 · Jeff Jonas, Sage CEO Sage has fielded positive data from two small late-stage studies of a drug aimed at a major market which involves 10% to 20% of all mothers giving birth in any... fqkbrc